CLL Coverage from Every Angle

Matthew S. Davids, MD, on Ibrutinib and Umbralisib in CLL or Mantle Cell Lymphoma

Posted: Sunday, October 4, 2020

Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses phase I/Ib data suggesting the doublet combination of ibrutinib and umbralisib is safe and active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma. He believes the combination warrants further study, particularly in those with BTK inhibitor–naive CLL or who are intolerant of or refractory to a venetoclax-based regimen.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.